1. Home
  2. All topics: A to Z
  3. Human papillomavirus

Human papillomavirus

Disease facts

Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union.

Read the factsheet

ECDC guidance on HPV vaccination in EU countries

This guidance partly complements and updates the 2008 and 2012 guidance documents on the introduction of HPV immunisation in EU/EEA Member States. It also covers the efficacy of the 9-valent vaccine, which was not licensed when the last guidance was published.

Read the guidance

European Immunization Week, 2020

The campaign is marked across Europe every April and aims to raise awareness of the importance of immunisation. ECDC supports the week by launching a new European Vaccination Information Portal with up to date information on human papillomavirus.

Read more

Latest updates

Data

Evidence of the immunogenicity of HPV vaccines in males

Table -

Data

Evidence of the efficacy of the 9vHPV vaccine

Table -

Data

Evidence of the safety of the 9vHPV vaccine

Table -

Data

Evidence of the safety of the HPV vaccine in HIV-infected men and women

Table -

Publication

Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction

Technical guidance -

Peer-Reviewed Publication

HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe

Jan 2019

Peer-Reviewed Publication

Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV

Aug 2015

Peer-Reviewed Publication

Safety of human papillomavirus vaccines: A review

Feb 2015

News

HPV vaccination in EU countries: review of new evidence

ECDC comment -

News

ECDC guidance on HPV vaccination: Focus on reaching all girlsArchived

Press release -

News

Detection of human papillomavirus DNA in urine. A review of the literatureArchived

ECDC comment -

News

Introduction of human papillomavirus vaccination in Nordic countriesArchived

ECDC comment -

News

EIW 2015 at ECDC

Campaign -

Data

Evidence of the immunogenicity of HPV vaccines in males

Table -

Data

Evidence of the efficacy of the 9vHPV vaccine

Table -

Data

Evidence of the safety of the 9vHPV vaccine

Table -

Data

Evidence of the safety of the HPV vaccine in HIV-infected men and women

Table -

Prevention and control

Two prophylactic HPV vaccines have been licensed in Europe, a bivalent and a quadrivalent vaccine: both have a good safety profile and protect against the high-risk HPV types 16 and 18.

Facts

Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union.

Scientific advice

Systematic reviews, expert opinions and public health guidance on human papillomavirus.

ECDC disease networks and programmes

Related topics

Disease groups

Vaccine-preventable diseases

2009 influenza A (H1N1) pandemic

Disease / public health area

Cholera

Disease / public health area

Congenital rubella syndrome (CRS)

Disease / public health area

Diphtheria

Disease / public health area

Hepatitis B

Disease / public health area

Invasive Haemophilus influenzae disease

Disease / public health area

Invasive pneumococcal disease

Disease / public health area

Japanese encephalitis

Disease / public health area

Measles

Disease / public health area

Meningococcal disease

Sexually Transmitted Infections

Disease / public health area

Chlamydia infection

Disease / public health area

Congenital syphilis

Disease / public health area

Gonorrhoea

Disease / public health area

Hepatitis B

Disease / public health area

Hepatitis C

Disease / public health area

HIV infection and AIDS

Disease / public health area

Lymphogranuloma venereum

Disease / public health area

Syphilis